Skip to main content

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Completed · Phase 1, Phase 2 · NCT04420884

Conditions: Solid Neoplasms

At a glance

Research payments reported, 2025
$3.5M
U.S. investigators named
24
Sites paid
21
Planned or actual enrollment
248

About the trial

Sponsor
Takeda
Tested
Dazostinag (drug), Pembrolizumab (drug), Platinum (drug), 5-fluorouracil (drug)
Dates
Started 2020-07-22; completion 2026-03-30
Results posted
Yes

The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated me…

From ClinicalTrials.gov, last updated 2026-10-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $3.5M in research payments for this study in 2025 (449 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.